A new nasal vaccine to prevent tuberculosis
Live nasal recombinant B. pertussis vaccine against tuberculosis
['FUNDING_OTHER'] · ILIAD BIOTECHNOLOGIES, LLC · NIH-10861885
This study is testing a new nasal vaccine to help protect adults from tuberculosis (TB) by boosting their immune response in the lungs, and it aims to be a better option than the current BCG vaccine.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ILIAD BIOTECHNOLOGIES, LLC (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10861885 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a live nasal vaccine using an attenuated strain of Bordetella pertussis to combat tuberculosis (TB) in adults. The approach aims to induce strong immune responses in the lungs, which are crucial for preventing TB infection and transmission. By utilizing a vaccine platform that has shown promise in previous clinical trials, the research seeks to create a more effective alternative to the current BCG vaccine. Patients may receive this vaccine intranasally, which could enhance its effectiveness in generating local immunity.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are at risk of tuberculosis infection.
Not a fit: Patients who are not adults or those who have already been vaccinated with BCG may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective vaccine that significantly reduces the incidence and spread of tuberculosis in adults.
How similar studies have performed: Previous studies using similar live vaccine platforms have shown promise, indicating potential for success in this novel approach.
Where this research is happening
NEW YORK, UNITED STATES
- ILIAD BIOTECHNOLOGIES, LLC — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GOLDSTEIN, PETER — ILIAD BIOTECHNOLOGIES, LLC
- Study coordinator: GOLDSTEIN, PETER
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.